FDA Approves Moderna’s mFLUSIVA mRNA Vaccine for Adults Aged 50 and Older
The U.S. Food and Drug Administration has approved forbes.com’s mFLUSIVA seasonal influenza vaccine for adults aged 50 and older, marking the country’s first regulatory authorization of an mRNA-based flu shot. According to statnews.com, the agency granted a standard, traditional approval for use in adults aged 50 to 64, alongside an accelerated approval for individuals aged … Read more